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Background: Zebrafish have been used as a vertebrate model to study human cancers such as melanoma,
rhabdomyosarcoma, liver cancer, and leukemia as well as for high-throughput screening of small molecules of
therapeutic value. However, they are just emerging as a model for human brain tumors, which are among the most
devastating and difficult to treat. In this study, we evaluated zebrafish as a brain tumor model by overexpressing a
human version of oncogenic KRAS (KRASG12V).
Methods: Using zebrafish cytokeratin 5 (krt5) and glial fibrillary acidic protein (gfap) gene promoters, we activated
Ras signaling in the zebrafish central nervous system (CNS) through transient and stable transgenic overexpression.
Immunohistochemical analyses were performed to identify activated pathways in the resulting brain tumors. The
effects of the MEK inhibitor U0126 on oncogenic KRAS were evaluated.
Results: We demonstrated that transient transgenic expression of KRASG12V in putative neural stem and/or progenitor
cells induced brain tumorigenesis. When expressed under the control of the krt5 gene promoter, KRASG12V induced
brain tumors in ventricular zones (VZ) at low frequency. The majority of other tumors were composed mostly of spindle
and epithelioid cells, reminiscent of malignant peripheral nerve sheath tumors (MPNSTs). In contrast, when expressed
under the control of the gfap gene promoter, KRASG12V induced brain tumors in both VZs and brain parenchyma at
higher frequency. Immunohistochemical analyses indicated prominent activation of the canonical RAS-RAF-ERK
pathway, variable activation of the mTOR pathway, but no activation of the PI3K-AKT pathway. In a krt5-derived
stable and inducible transgenic line, expression of oncogenic KRAS resulted in skin hyperplasia, and the MEK inhibitor
U0126 effectively suppressed this pro-proliferative effects. In a gfap-derived stable and inducible line, expression of
oncogenic KRAS led to significantly increased mitotic index in the spinal cord.
Conclusions: Our studies demonstrate that zebrafish could be explored to study cellular origins and molecular
mechanisms of brain tumorigenesis and could also be used as a platform for studying human oncogene function and
for discovering oncogenic RAS inhibitors.
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Brain tumors account for approximately 90% of all CNS
tumors. According to the National Cancer Institute, there
have been 23,130 new cases of brain tumors and other
nervous system cancers in 2013 with 14,080 deaths occur-
ring in the United States alone (http://www.cancer.gov/* Correspondence: michael.taylor@wisc.edu
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unless otherwise stated.cancertopics/types/brain). The inaccessibility of some
brain tumors to surgery, limitations in drug delivery
due to presence of the brain–blood barrier (BBB), and the
malignant nature of some tumor types make brain tumors
especially hard to treat. For example, children with diffuse
intrinsic pontine glioma (DIPG) and adults with glioblast-
oma multiforme (GBM) have a dismal prognosis, and no
significant progress has been made over the past several
decades to improve survival rates [1,2].
Although Ras mutations are uncommon in human brain
tumors, activation of the canonical Ras pathway throughis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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human glioblastoma development [3]. By activating these
pathways, several mouse glioma models have been gen-
erated, primarily through overexpression of oncogenic
KRAS [4-7].
Zebrafish have emerged as an important model to study
human cancers and to understand tumorigenic mecha-
nisms [8] and the Ras pathway activation had been suc-
cessfully used to induce melanoma [9], pancreatic cancer
[10], embryonal rhabdomyosarcoma [11], and liver cancer
[12]. To evaluate whether zebrafish could be used as a
brain tumor model, we expressed the human version of
KRASG12V driven by the zebrafish krt5 promoter that we
recently identified [13] and also by the well-characterized
gfap gene promoter [14]. We demonstrated that zebrafish
develop high-grade brain and other cranial tumors with
variable penetrance in transient transgenic fish, which
was promoter dependent. We also showed that U0126,
a MAP kinase (MEK) inhibitor, could suppress the pro-
proliferative effects of oncogenic KRAS, suggesting zeb-
rafish could potentially be used as in vivo models to
screening for Ras inhibitors that may prove to be of thera-
peutic value to a variety of human cancers with activated
RAS signaling, including certain types of brain tumors.
Results
Zebrafish krt5 promoter drives transgenic expression in
the brain
Zebrafish krt5 gene shares conserved synteny with its
mammalian counterparts [15]. Based on in situ hybridiza-
tion, krt5 is expressed in skin epithelial cells, neurons and
glial cells of the brain and spinal cord, and chondrocytes
of the skull [16]. Using a transgene consists of a 4.9 kb
fragment of the krt5 gene promoter and EGFP reporter,
we developed two stable transgenic lines, Tg(−4.9krt5:
EGFP), both showing EGFP expression that faithfully reca-
pitulates the endogenous krt5 expression pattern in skin
epithelial cells (Additional file 1: Figure S1A), radial
glial cells (Additional file 1: Figure S1B), and chondro-
cytes (Additional file 1: Figure S1C). Unlike the well-
characterized zebrafish gfap and nestin promoters that
drive strong expression during early stages of brain devel-
opment [14,17], our Tg(−4.9krt5:EGFP) lines showed EGFP
expression in only a subset of neural cells (Additional
file 1: Figure S1B, S1C). In adults, EGFP expression was
found in the optic tectum (OT) and the dorsal side of
the midbrain and hindbrain boundary (Figure 1A). On
the ventral side of the brain, EGFP was prominent in
the ventral regions lining the ventricular zones (VZ) of
the midbrain and hindbrain and in the lobus inferior
(LI) of the hypothalamus in a pattern similar to the zebra-
fish midkine gene [18] (Figure 1B). Sagittal sections of the
adult brain confirmed expression on the surface of the OT
and in the VZs (Figure 1C). EGFP-positive cells in thebrain VZs were morphologically similar to radial glial cells
and their expression patterns partially overlap with the
radial glia marker S100β (Figure 1D).
Overexpression of KRASG12V in krt5-expressing cells leads
to malignant tumors of cranial cavity
We used a co-injection strategy to deliver Tol2-based Tg
(krt5:Gal4VP16) and I-SceI meganuclease-based Tg(UAS:
mCherry-KRASG12V) constructs into individual single-cell
embryos (Figure 2A). Each embryo received approxi-
mately 20 pg of the combined plasmid DNA, as higher
\doses caused severe abnormalities and high mortality.
When transiently expressed in zebrafish embryos, krt5
drove mCherry expression prominently in skin epithe-
lial cells and other cell types, including cells in the
brain when observed at 24 hours post-fertilization (hpf )
(Figure 2B,B’). Despite this broad expression, we only
observed gross tumor formation in the head region.
The earliest sign of tumorigenesis was observed in a 9-
day-old larva that showed a tumor mass between the eye
and the ear (Figure 2C, C’). By approximately 1 month of
age, 25.8% (n = 17/66) of fish began to develop tumors. By
2 months of age, tumors in some fish were visible to the
naked eye (Figure 2D) and emitted strong mCherry fluor-
escence when observed under a fluorescence microscope
(Figure 2D’). At 1 year of age, tumors were seen in ap-
proximately 50% of transient transgenic fish (Figure 2F).
Hematoxylin and eosin (H&E) staining of paraffin sec-
tions from 15 tumor-bearing fish revealed 3 cases (20%,
Table 1) with tumors originating from the brain region.
These tumors infiltrated the VZ and exhibited histopatho-
logical features of glial tumors (Figure 3A-B). Despite this
striking similarity in morphology, the 3 brain tumors did
not show prominent expression of the glial markers of
GFAP and S100β (Additional file 1: Figure S2A-B). The
other 12 tumors exhibited biphasic cell morphology, with
spindle cells mingling with epithelioid cells (Additional
file 1: Figure S3A-D). These tumors usually possessed
abundant mitotic figures (Additional file 1: Figure S3B) and
were often locally invasive and spread to adjacent soft
tissue (Additional file 1: Figure S3A) or gills (Additional
file 1: Figure S3C). The spindle cell morphology and in-
vasive nature of the tumors were reminiscent of zebra-
fish MPNSTs [19].
Overexpression of KRASG12V in gfap-expressing cells leads
to parenchymal brain tumors
The low frequency of brain tumors from the krt5
gene promoter prompted us to test whether the well-
characterized, broadly-expressing promoter of zebrafish
radial glia gene gfap could induce higher tumor inci-
dence [14]. As expected, the gfap promoter directed trans-
genic expression throughout the CNS (Figure 2B,B’).
Despite strong expression of the oncogene, only about
Figure 1 Expression pattern of Tg(krt5:EGFP) in the adult zebrafish brain. (A) Dorsal view (anterior to the left) of a 6-month-old transgenic
fish brain showing EGFP expression in the ventricular zone (VZ) of the midbrain and hindbrain (arrow). Inset shows the bright-field view of the
same brain. (B) Ventral view (anterior to the left) of the same brain as in (A) showing EGFP expression in the lobus inferior (LI) of the hypothalamus
(arrow) and VZ of the hindbrain. (C) A sagittal section through the adult brain showing EGFP expression in the optic tectum (OT), cerebellum (Ce), and
VZ. (D) Enlarged view of framed area in (C) showing overlapping EGFP expression and antibody staining for the radial glia marker S100β (red). Scale
bars, 200 μm for A-C; 20 μm for D.
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the head region at 1 year of age (Figure 2E, E’), making
the overall tumor penetrance of transient Tg(gfap:
Gal4VP16; UAS:mCherry-KRASG12V) transgenic fishsimilar to that of tumors from Tg(krt5:Gal4VP16;
UAS:mCherry-KRASG12V) (Figure 2F).
Analysis of H&E-stained paraffin sections revealed that
6 of 10 gfap-derived tumors were brain tumors (Table 1).
Figure 2 Transient expression of oncogenic KRAS results in tumorigenesis in the brain region. (A) Graphic representation of driver and
effector DNA constructs used for co-injection into zebrafish eggs. (B, B’) The krt5 gene promoter directed prominent transgenic expression in skin
epithelial cells and other cell types, whereas the gfap promoter directed expression primarily in the CNS. (C, C’) A 9-day old krt5-transgenic fish
showing focal expression of the oncogenic mCherry-KRAS in the head (outlined in white). (D, D’) A krt5-transgenic fish at 2 months of age showed
gross tumor infiltration within the head. (E, E’) A gfap-transgenic fish at 2 months of age showed similar tumor infiltration in the head. (F) Both
krt5- and gfap-transgenic fish developed tumors within the head region at approximately 50% penetrance by 15 months of age. Scale bars, 0.5 cm.
Table 1 KRAS-induced tumors in zebrafish and
immunohistochemical characterization of brain tumors
Promoters krt5 gfap
Tumors analyzed 15 10
Number of brain tumors 3 (20%) 6 (60%)
MPNST-like 12 (80%) 1 (10%)
Others 0 (0%) 3 (30%)
pERK1/2 3/3 (+++) 6/6 (+++)
pAKT (Ser473) 0/3 0/6
p4E-BP1 3/3 (++) 6/6 (++)
pS6RP 3/3 (+) 6/6 (5+; 1+++)
Immunofluorescence levels: +++, strong; ++ intermediate; + low and sporadic.
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the brain (Figure 3C), consistent with the strong and ubi-
quitous nature of the gfap promoter. The neoplasms con-
sisted of moderately pleomorphic cells with an infiltrative
growth pattern. Mitotic activity was abundant (Figure 3D)
and necrosis was encountered (Figure 3E, 3 F) in selected
tumors, yet microvascular infiltration was largely absent.
These overall characteristics were consistent with that
seen in human high grade astrocytomas. Despite the pre-
sumed radial glial cell of origin and glial histomorphology,
none of the tumors showed notable GFAP or S100β ex-
pression (Table 1). Among 4 peripheral tumors, 1 exhib-
ited MPNST-like spindle cell morphology (Additional
file 1: Figure S4A-B), while the other 3 consisted of un-
differentiated neoplasms that were difficult to classify
(Additional file 1: Figure S4C-D).
Figure 3 Histological and immunohistological analyses of tumors from krt5 and gfap transgenic fish. (A) H&E staining of a sagittal section
from a 6-month-old krt5-derived tumor showing tumor cells originating from and infiltrating the VZ of the optic tectum (OT), as highlighted by
the dotted line. (B) Enlarged view of the white frame in (A) demonstrating infiltrating malignant cells with moderate pleomorphism, typical of
high-grade astrocytoma. (C) A 6-month-old gfap-transgenic fish brain showing tumor development in both the VZ (broken line) and the brain
parenchyma (arrow). gfap:KRASG12V-derived brain tumors exhibited phenotypes consistent with malignant glioma including frequent mitotic figures
(D) and focal necrosis (E, F). N, necrosis. Scale bars, 100 μm for A; 20 μm for B, D, E and F; 40 μm for C.
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In mouse models of oncogenic Kras-induced glioma,
tumor cells have increased expression of both phosphory-
lated ERK and phosphorylated AKT [7,20], indicating acti-
vation of the canonical Ras and PI3K-AKT pathways. To
determine whether these pathways were simultaneously
activated in zebrafish tumors, we performed extensive im-
munohistochemical analysis on tumor samples with anti-
bodies against the downstream targets of these pathways.
We found that both krt5- and gfap-derived brain tumors
showed prominent phospho-ERK1/2 expression (Table 1
and Figure 4B,E). Next, we analyzed the PI3K-AKT path-
way activation in brain tumors using a previously validatedanti-phospho-AKT (Ser473) antibody [21] (Additional
file 1: Figure S2C). None of the 9 brain tumors examined
showed positive staining, suggesting that the PI3K-AKT
pathway was not activated (Additional file 1: Figure S2D).
However, all tumor samples were positive for phospho-
4E-binding protein 1 (p4E-BP1; Figure 4C) and phospho-
ribosomal protein S6 (pS6RP; Figure 4F), which are targets
of the mammalian target of rapamycin (mTOR) pathway
[22]. Unlike the prominent phospho-ERK1/2 staining,
p4E-BP1 and pS6RP showed variability among tumor
samples (Table 1). These results suggested that activation
of the canonical Ras pathway and the mTOR pathway play
key roles in KRAS- induced brain tumors in zebrafish.
Figure 4 Activation of the Ras and mTOR pathways in brain tumors. (A) A 6-month-old krt5-derived brain tumor infiltrating both the ventral
brain and the VZ. Tumor cells exhibited prominent expression of phospho-ERK1/2 (B) and phospho-4E-BP1 (C). (B) and (C) show immunofluorescence
staining of the white framed region in (A). Note the relatively normal cerebellum exhibited much less staining for the two antibodies. (D) A 12-month-
old gfap-derived brain tumor showed tumor cell infiltration of the VZ surrounding the OT. Tumor cells exhibited prominent expression of pERK1/2 (E)
and pS6RP (F). Note that paraffin sections were used for immunofluorescence. Ce, cerebellum; OT, Optic tectum. Scale bars, 200 μm for A; 40 μm for B,
C, D, and E.
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screening
Since we did not expect that stable transgenic fish overex-
pressing the oncogenic KRAS to survive to adulthood, we
further generated transgenic lines that allow Doxycyc-
line (Dox) inducible expression of oncogenic KRAS in
krt5- and gfap-expressing cells using the TetOn system
(Figure 5A). In the presence of 10 μg/ml of Doxycycline
starting from early gastrula stage, Tg(krt5:rtTA;TRE:
mCherry-KRAS G12V) embryos showed weak mCherry
expression in skin epidermal cells and skin hyperplasia
was visible at 24hpf. Skin hyperplasia became more
conspicuous at 48hpf, especially at the ventral yolk sac
(Figure 5B). This hyperplasia could be effectively elimi-
nated by treating embryos simultaneously with 50 μM
of U0126 (Figure 5B-C; Additional file 1: Figure S5A-B,
n = 24), a strong MEK inhibitor that blocks ERK phos-
phorylation when applied at the early gastrula stage of
zebrafish embryonic development [23].
We also generated a Tg(gfap:rtTA;TRE:mCherry-
KRAS G12V) line. Embryos from this line showed strong
mCherry expression throughout the CNS at 24hpf in the
presence of Dox. At 72hpf, transgenic larvae exhibited
heart edema, body curvature and hyperpigmentation of
the trunk, and these phenotypes were more obvious at
120hpf (Figure 6A-B). Sagittal sectioning of 72hpf larvae
revealed that expression of oncogenic KRAS in CNSresulted in abnormal expression of GFAP (Figure 6C,E),
and significantly increased mitotic figures in the spinal
cords as indicated by immunostaining for phosphorylated
Histone 3 (pH3) (Figure 6D,E). The mitotic figures in a
10 μm section spanning a region above the yolk sac in-
creased from 1 ± 0.71 (n = 4) to 26 ± 9.80 (n = 6) (unpaired
student’s t-test, p < 0.001). Surprisingly, increased mitosis
was only observed in the region corresponding to strong
endogenous GFAP expression, but not in brain regions
showing negligible GFAP expression (Figure 6E-F). We
attempted to evaluate whether U0126 treatment could re-
duce mitotic activities. Though the effective dosage of
100 μM applied at the early gastrula stage could reduce
the mCherry levels in CNS (Additional file 1: Figure
S6C-D), it also caused severe developmental defects by
48hpf. A much lower dose of 5 μM of U0126 was much
less toxic, but did not significantly reduce the mitotic
index (Data not shown).
Discussion
In this study, we report that human oncogenic KRAS
driven by the zebrafish krt5 or gfap promoter induces ma-
lignant tumors of the nervous system. We demonstrated
that the canonical Ras and mTOR signaling pathways
were activated in tumors driven by both promoters. Fur-
thermore, we generated inducible transgenic lines that ex-
hibited epithelial hyperplasia in skin and increased mitotic
Figure 5 MEK inhibitor U0126 suppresses proliferative effect of oncogenic KRAS in skin epithelial cells. (A) Graphic representation of driver
and effector DNA constructs for generation of Dox-inducible stable transgenic lines. (B, C) In an inducible Tg(krt5:rtTA:mCherryKRASG12V) transgenic line,
48hpf larvae treated with 10 μg/ml Dox showed skin hyperplasia, most noticeably under the yolk sac (arrows). 50 μM U0126 treatment completely
eliminated the skin hyperplasia (arrow heads). Scale bar, 250 μm.
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showed that the MEK inhibitor U0126 suppressed the
pro-proliferative effects of oncogenic KRAS in early em-
bryonic development.Tumor types generated by oncogenic KRAS
The combined features of diverse tumor cell morphology,
high cellularity, presence of mitotic figures and regional
necrosis indicate that the onogenic KRAS-induced tumors
are most likely malignant gliomas. Yet, the absence of
GFAP and S100β expression in the adult brain tumors is
intriguing. Both human and mouse models of glioma can
lose GFAP expression with tumor progression either
through epigenetic regulation [24] or tumor cell dediffer-
entiation [25]. Oncogenic KRas has also been found to
cause defects in terminal differentiation of stem or pro-
genitor cells in mouse colon [26] and zebrafish pancreatic
[10] cancer models, so it is possible that GFAP expression
was lost early during oncogenic KRAS-driven brain
tumorigenesis. We also analyzed early stages of brain tu-
mors at 18 days post-fertilization (dpf) and 30 dpf respect-
ively, but found no obvious GFAP expression associated
with tumorigenesis (Data not shown). Although oncogenic
KRAS-induced brain tumors reported in this study resem-
bled astrocytoma morphologically, we cannot exclude the
possibility that they are a type of undifferentiated braintumors, such as primitive neuroectodermal tumors
(PNET) which often do not express GFAP [27].
The other KRAS-derived tumors with spindle cell
morphology were compatible with human MPNSTs,
which are aggressive nerve sheath tumors associated
with activation of the RAS pathway. While MPNSTs gen-
erally arise in the setting of inactivating mutations in the
neurofibromatosis 1 (NF1) gene [28], others have demon-
strated that Kras is an important determinant of survival
in MPNST [29]. Zebrafish carrying mutations in tp53 [19]
and several ribosomal protein genes [30] spontaneously
develop MPNSTs in abdominal cavities or peri-ocular re-
gions. Tumors observed in our transgenic fish represent
another type of MPNST that could have a neural crest ori-
gin as the krt5 promoter drives transgenic expression
along this lineage (Additional file 1: Figure S1C).
Cell origin and mechanism of brain tumorigenesis
Brain tumors can originate from specific brain regions
and from different cell types [31]. There is heterogeneity
in progenitor cell subtypes in the ventricular zone of
the zebrafish adult telencephalon and other brain re-
gions [32]. From the observation of a limited number
of brain tumors, it appeared that krt5-derived tumors
mostly originated from VZ, while gfap-derived tumors
may have originated from both the VZ and brain paren-
chyma. These brain tumors exhibited different histological
Figure 6 Oncogenic KRAS expression in CNS increases mitotic activity in the spinal cords. (A, B) 120hpf larvae from an inducible Tg(gfap:
rtTA:mCherryKRASG12V) line showed heart edema (arrow), body curvature, and hyperpigmentation of the trunk. At 72hpf, wild-type larvae showed
prominent expression of GFAP in the spinal cord (C), and few cells were undergoing mitosis (D). Expression of oncogenic KRAS disrupted the normal
GFAP expression pattern in the spinal cord (E), and significantly increased the number of cells undergoing mitosis (F, arrows). SC, spinal cord. Scale
bars, 250 μm.
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gin affects tumor cell phenotypes [33].
The Ras and PI3K-AKT pathways are interconnected
and converge on mTOR signaling to control tumor cell
growth [34]. A previous study shows that zebrafish Kras-
induced liver tumors had simultaneous activation of the
Ras and PI3K-AKT pathways [35]. Our immunohisto-
chemical analyses revealed no activation of the PI3K-AKT
pathway, but showed increased expression of p4E-BP1
and pS6RP, two main targets of the mTOR pathway.
There is the possibility that these two targets were acti-
vated by Ras itself, as RAS has been shown to be able to
activate mTOR downstream targets through both mTOR-
dependent and independent mechanisms [36].
In mouse models of Kras-induced glioma, expression of
oncogenic Ras is often insufficient for malignant glioma-
genesis [6]. Our current study demonstrated that onco-
genic KRAS itself was sufficient to initiate gliomagenesisin transient transgenic situations, albeit with rather long
latencies. Surprisingly, a previous study using the zebrafish
nestin promoter to drive conditional expression of the
zebrafish version of KrasG12V did not result in brain tu-
mors [37]. Our current study also showed that gfap-driven
expression of oncogenic KRAS in a stable line did not lead
to increased mitosis during early brain development.
These findings raise the issue that other oncogenic events
may be needed for efficient brain tumorigenesis in zebra-
fish. Since the constitutively active form of AKT is
required for mouse gliomagenesis [6,20], it will be in-
teresting to test whether brain tumor penetrance and
malignancy could be enhanced by co-activation of the
PI3K-AKT pathway.
Zebrafish tumor models for drug screening
A distinct advantage of zebrafish cancer models lies in
their ability to be used for screening small molecules to
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in a relatively high-throughput manner [38]. Recent drug
screening efforts in zebrafish have uncovered small mole-
cules that can potentially be used to treat human melan-
oma [39] and leukemia [40]. The krt5-derived transgenic
line with the early skin hyperplasia phenotype could be
explored as an in vivo platform to screen for oncogenic
KRAS inhibitors [41]. As for the gfap-derived transgenic
line, larvae as early as 72 hpf had significantly increased
mitotic activity, as indicated by a dramatic increase of
pH3-positive cell numbers in the spinal cord (Figure 6).
Since pH3 immunostaining has been successfully used as
a marker for high-throughput chemical screenings in zeb-
rafish [42], we believe our transgenic line could be further
evaluated for screening small molecules that inhibit the
mitotic effects of oncogenic KRAS in the CNS. Drug leads
from these screening can then be used for identifying can-
didates that penetrate into the brain, as zebrafish also pos-
sess a functional BBB expressing multidrug resistance
proteins [43,44].
Conclusions
Our study showed that oncogenic KRAS promoted brain
tumors in zebrafish, and that tumorigenesis was driven
by the activation of the canonical Ras and mTOR path-
ways. Zebrafish provide an invaluable model for under-
standing brain tumor cell origin, mechanisms of brain
tumorigenesis, and may serve as in vivo platforms for
studying cancer gene functions and for screening drugs
to inhibit the oncogenic effects of RAS mutations.
Methods
Zebrafish husbandry
The AB strain was purchased from the Zebrafish Inter-
national Resource Center (ZIRC, Eugene, OR). Embryos
and larvae were maintained at 28.5°C in egg water
(0.03% Instant Ocean). All experiments on transgenic
expression of oncogenes and handling of transgenic fish
with tumors were approved by the St. Jude Children’s
Research Hospital Institutional Animal Care and Use
Committee.
Plasmid DNA construction and transgenesis
The Gateway system was adapted to generate promoter-
containing driver constructs [45]. The krt5 and gfap pro-
moter sequences were inserted into p5E and the Gal4VP16
sequence was inserted into pME. The p5E vectors contain-
ing the respective promoters and the pME-Gal4VP16 were
combined with the 3’ entry clone p3E-polyA and the des-
tination vector pDestTol2pA2 to create the construct krt5:
Gal4VP16, gfap:Gal4VP16 using the LR Clonase II Plus
Enzyme mix (Invitrogen, Carlbad, CA). The pIUI-
mCherry-KRASG12V effector construct was made withthe I-SceI meganuclease system as previously described
[21]. About 20 pg of combined driver and effector plasmid
DNA together with about 30 pg of Tol2 transposase
mRNA and 0.001 unit of I-SceI meganuclease (New
England BioLabs) were injected into 1-cell stage eggs in
1–2 nl volume.
To generated stable transgenic lines, we adopted the
Clontech Tet-On® inducible system (Clontech, Montain
View, CA). Briefly, the Tet-On fragment of the pTet-On®
advanced vector (CAT No. 631069) was cloned into the
pME of the gateway system to generate the krt5:Tet-OnAD
and gfap: Tet-OnAD driver constructs. The TRE-Tight
fragment from the pTRE-Tight vector (CAT No. 631059)
and the mCherryKRASG12V oncogene were directly
cloned into the pT2AL200R150G vector [46] to generate
the TRE:mCherryKRASG12V effector construct. The driver
and effector constructs were co-injected into 1-cell-stage
eggs. Stable transgenic fish were selected from F1 embryos
showing mCherry expression after treatment with 10 μg/
ml doxycycline (Clontech, Mountain View, CA).Brain tumor pathology and immunohistochemistry
Zebrafish harboring tumors were euthanized using 0.04%
Tricaine and fixed in 4% paraformaldehyde for 2 days. Fish
were then decalcified using 0.5 M EDTA (AMRESCO®)
for 5 days, rinsed in phosphate buffered saline, dehy-
drated, and paraffin wax embedded. 5 μm sections were
stained using hematoxylin and eosin (H&E). Immuno-
fluorescence on paraffin sections and cryosections were
conducted using the Cell Signaling Technology protocol
that accompanies the purchased antibodies. The primary
anti-rabbit antibodies used are: GFAP (Dako, Z0334,
1:1000), S100 (Dako, Z0311, 1:2000), pERK1/2 (Cell Sig-
naling, 4370, 1:200), pAKT (Ser473) (Cell Signaling, 4060,
1:200), pS6RP (Cell Signaling, 2211, 1:200), p4E-BP1 (Cell
Signaling, 2855P, 1:200), and pH3(Ser10) (Cell Signaling,
9701, 1:50). The secondary antibodies used are Alexa
Fluor®488 (A-11034) and Alexa Fluor®568 (A-11011) anti-
Rabbit IgG (H + L) (Life Technologies, 1:2000).Doxycycline and U0126 treatment of embryos
Doxycycline (Clontech, Mountain View, CA) was dis-
solved in distilled water at the stock concentration of
10 mg/ml. Doxycycline at the final concentration of
10 μg/ml (unless stated otherwise) were added to embryos
at the early gastrula stage to induce transgenic expression.
The MEK inhibitor U0126 (LC labs, Woburn, MA) was
dissolved in DMSO at a stock concentration of 100 mM.
Early gastrula-stage embryos were either treated with
Doxycycline alone to induce transgenic expression or
treated with the combination of Dox and 50–100 μM
U0126 to show oncogenic KRAS inhibition.
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Additional file 1: Figure S1. Tg(krt5-EGFP) expression during
development. (A) Lateral view of a 72 hpf larva showing EGFP expression in
skin epithelial cells. (B) A72 hpf larva showing sporadic EGFP expression in
brain (arrows). (C) A 3-week-old juvenile showing EGFP expression in brain
radial glial cells (arrow) and chondrocytes (arrowhead). OT, optic tectum; DI,
diencephalon. Scale bars, 1 mm, A; 100 μm, B and C. Figure S2. Antibody
cross-reactivity in tumor paraffin-sections. (A) A krt5-derived tumor showing
GFAP reactivity at the ventricular zone (arrow), not tumor mass. (B) The
same tumor showing S100β reactivity at the ventricular zone (arrow), not
tumor mass. (C) A tumor from coexpression of oncogenic smoothened and
AKT1 showing expression of pAKT(S473). (D) A gfap-derived tumor was
negative for pAKT(S473). OT, optic tectum. Scale bars, 40μm. Figure S3.
Expression of krt5:KRASG12V resulted in MPNST-like tumors. (A) A 6-month-
old fish showing a tumor in anterior trunk. (B) Tumor cells exhibits spindle,
epithelioid cell morphologies with mitotic figures (arrows). (C) An 8-month-
old tumor obliterated the ventral brain, invaded the gills. (D) Enlarged view
of tumor in (C) showing spindle, epithelioid cells and mitotic figure (arrow).
Scale bars, 200 μm, A, C; 20 μm, B, D. Figure S4. Expression of gfap:
KRASG12V resulted in undifferentiated neoplasms. (A) A 12-month-old
fish showing a large tumor mass in the anterior trunk. (B) Tumor cells
exhibits spindle, epithelioid cell morphologies. (C) A 4-month-old tumor
infiltrated the lower jaw. (D) Enlarged view of (C) showing compact and
round tumor cells. Scale bars, 200μm, A, C; 20 μm, B, D. Figure S5. KRAS
inhibition in stable transgenic fish. (A, B) 48 hpf Tg(Krt5:rtTA:mCherryKRASG12V)
transgenic larvae showing skin hyperplasia (arrows), which was eliminated by
50μM U0126 treatment. (C, D) In Tg(gfap:rtTA:mCherryKRASG12V) stable line,
100μM U0126 treatment reduced KRAS expression in CNS, but caused
developmental defects.
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